<DOC>
	<DOCNO>NCT02393833</DOCNO>
	<brief_summary>The serum protein research study substudy core study 'Maintenance Chemotherapy Hormone Non-responsive Breast Cancer ' . This substudy evaluation blood protein relationship breast cancer treatment . It assess level Vascular Endothelial Growth Factor ( VEGF ) , Soluble HER2 Protein ( NRP , neu-related protein ) Vascular Cellular Adhesion Molecule-1 ( VCAM-1 ) serum sample patient ' blood different time point . The goal evaluate difference serum level patient receive maintenance chemotherapy . The serum level also examine determine vary three year period evaluation . In addition , serum level patient recurrence breast cancer compare remain disease free . The information obtain study enable breast cancer physicians well tailor therapy future patient .</brief_summary>
	<brief_title>Serum Protein Research Substudy</brief_title>
	<detailed_description>The Serum Substudy ass level Vascular Endothelial Growth Factor ( VEGF ) , Soluble HER2 Protein ( NRP , neu-related protein ) Vascular Cellular Adhesion Molecule-1 ( VCAM-1 ) patient ' serum sample different time point . VEGF : Angiogenesis play central role tumor progression solid neoplasia . The switch avascular vascular phase generally accompany rapid primary tumor growth local invasiveness . Furthermore , angiogenesis also necessary begin end development distant metastasis implicate phenomenon dormant micrometastases . Antiangiogenic peptide may alter serum urine cancer patient . In study 144 breast cancer patient , angiogenic protein basic fibroblast growth factor abnormally elevate urine 29 % case serum 10 % . Another angiogenic protein , vascular endothelial factor ( VEGF ) , abnormally elevate serum 70 % breast cancer patient ( 4 ) . Since platelet bind VEGF , platelet value also assay . HER2-ECD : No data available regard presence serum HER2-ECD ( NRP ) level c-erbB2 negative tumor , extracellular domain c-erbB2 oncogene product ( NRP ) detectable sera 30-60 % patient cerbB2 positive tumor . Many report correlate elevated serum level cerbB2 gene amplification c-erbB2 overexpression tumor . These data support hypothesis level NRP protein reflect presence c-erbB2 positive cell modification factor predict decrease c-erbB2 positive cell standard adjuvant chemotherapy . Moreover , change detectable NRP maintenance phase suggest possible modification biology and/or behaviour hypothetic micrometastasis . VCAM-1 : In tumor , endothelial VCAM-1 play major role adhesion leukocytes endothelium , suggest relationship cellular adhesion angiogenesis . Soluble VCAM-1 implicate mediation angiogenesis study support hypothesis VCAM-1 provide surrogate marker endothelial activation angiogenesis occur cancer . Recently , VCAM-1 serum level associate microvessel density response endocrine therapy .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Patient must randomize core protocol . Written inform consent serum substudy must sign dated patient investigator Patient must begin CM maintenance ( randomize CM maintenance ) Patient randomize core protocol Patient already begin CM maintenance ( randomize CM maintenance )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vascular endothelial growth factor ( VEGF )</keyword>
	<keyword>Vascular cell adhesion molecule-1 ( VCAM-1 )</keyword>
	<keyword>HER2-ECD</keyword>
</DOC>